Superior stroke prevention with angiotensin receptor blockers compared with other antihypertensive drugs

References

• Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903–1913.
   PubMed Web of Science ®Google Scholar
• Virani SS, Alonso A, Aparicio HJ, et al. Heart disease and stroke statistics-2021 update: a report from the American Heart Association. Circulation. 2021;23:e254–e743.
   Google Scholar
• Whelton PK, Carey RM, Aronow WS, et al. American College of Cardiology/American Heart Association guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive Summary. Circulation. 2017;2018(138):e426–e483 .
   Google Scholar
• Williams B, Mancia G, Spiering W, et al. ESC/ESH guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. 2018;39:3021–3104.
   PubMed Web of Science ®Google Scholar
• Kleindorfer DO, Towfigi A, Lombardi-Hill D, et al. guideline for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke. 2021;52:e364–e467.
   PubMed Web of Science ®Google Scholar
• Ravenni R, Jabre JF, Casiglia E, et al. Primary stroke prevention and hypertension treatment: which is the first-line strategy? Neurology Int. 2011;3:e12.
   PubMedGoogle Scholar
• Chrysant SG. Possible pathophysiologic mechanisms supporting the superior stroke protection of angiotensin receptor blockers compared to angiotensin-converting enzyme inhibitors: clinical and experimental evidence. J Human Hypertens. 2005;19:923–931.
   PubMed Web of Science ®Google Scholar
• Nickenig G, Ostergren J, Struijker-Boudier H. Clinical evidence for the cardiovascular benefits of angiotensin receptor blockers. J Renin-Angiotensin-Aldosterone Syst. 2006;7(Suppl 1):S1–S7 .
   PubMed Web of Science ®Google Scholar
• Chrysant SG. The pathophysiologic role of the brain renin-angiotensin system in stroke protection: clinical implications. J Clin Hypertens. 2007;9:454–459.
   Google Scholar
• Dahloff B. Prevention of stroke: new evidence. Eur Heart J. 2009;11(SupplF):F33–F38 .
   Google Scholar
• Unger T, Badoer F, Ganten D, et al. Brain angiotensin: pathways and pharmacology. Circulation. 1988;77(6, Part 2):I40–I54 .
   PubMedGoogle Scholar
• Frough G, Pinto JT, Le Y, et al. Chymase-dependent production of angiotensin II: an old enzyme in old hearts. Am J Physiol Heart Circ Physiol. 2017;312(2):H223–H231 .
   PubMedGoogle Scholar
• Thone-Reineke C, Steckelings UM, Unger T. Angiotensin receptor blockers and cerebral protection in stroke. J Hypertens. 2006;24(Suppl 1):S115–S121 .
   Google Scholar
• Ma Z, Viswanathan G, Sellig M, et al. β-arrestin-mediated angiotensin II type 1 receptor activation promotes pulmonary vascular remodeling in pulmonary hypertension. JACCBasic Transl Sci. 2021;6:854–869.
   Google Scholar
• Gonzalez-Blazquez R, Alcala M, Cardenas-Rebollo JM, et al. AT2R stimulation with C21 prevents arterial stiffening and endothelial dysfunction in the abdominal aorta from mice fed a high-fat diet. Clin Sci. 2021;135(24):2763–2780.
   Google Scholar
• Li J, Culman J, Hortnag H, et al. Angiotensin AT2 receptor protects against cerebral ischemia induced neuronal injury. FASEB. 2005;19(6):617–619.
   PubMedGoogle Scholar
• Fournier A, Messerli FH, Achard JM. Cerebroprotection mediated by angiotensin II. A hypothesis supported by recent randomized clinical trials. J Am Coll Cardiol. 2004;43(8):1343–1347.
   PubMedGoogle Scholar
• Alhusban A, Fouda AY, Pillai B, et al. Compound 21 is peo-angiogenic in the brain and results in sustained recovery after ischemic stroke. Journal of Hypertension. 2015;33(1):170–180.
   PubMedGoogle Scholar
• Bennion DM, Steckelings UM, Summers C. Neuroprotection via AT2 receptor agonists in ischemic stroke. Clin Sci. 2018;132(10):1055–1067.
   PubMed Web of Science ®Google Scholar
• Ahmed HA, Ishrat T, Pillai B, et al. Angiotensin receptor (AT2R) agonist C21 prevents cognitive decline after permanent stroke in aged animals-a randomized double-blind-preclinical study. Behav Brain Res. 2019;359:560–569.
   PubMedGoogle Scholar
• Eldahshan W, Ishrat T, Pillai B, et al. Angiotensin II type 2 receptor stimulation wit compound 21 improves neurological function after stroke in female rats: a pilot study. Am J Physiol Heart Circ Physiol. 2019;316(5):H1192–H1201 .
   PubMedGoogle Scholar
• Scotti L, Bassi L, Soranna D, et al. Association between renin-angiotensin-aldosterone system inhibition and risk of dementia: a meta-analysis. Pharmacol Res. 2021;166:105515.
   PubMedGoogle Scholar
• Jckson-Cowan LD, Ekdahshan W, Dumanli S, et al. Delayed administration of angiotensin receptor (AT2R) agonist C21 improves survival and preserves sensorimotor outcomes in female rats post-stroke through modulation of microglial activation. Int J Mol Sci. 2021;22(3):1356.
   PubMedGoogle Scholar
• Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lance. 2002;359(9311):995–1003.
   PubMed Web of Science ®Google Scholar
• Kjeldsen SE, Dahlof B, Devereux RB, et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy. A Losartan Intervention For Endpoint Reduction (LIFE) sub-study. JAMA. 2002;288(12):1491–1498.
   PubMed Web of Science ®Google Scholar
• Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003;21(5):875–886.
   PubMed Web of Science ®Google Scholar
• Papademetriou V, Farsang C, Elmfeldt D, et al. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in the elderly patients with isolated systolic hypertension. The Study on Cognition and Prognosis in the Elderly (SCOPE). J Am Coll Cardiol. 2004;44(6):1175–1180.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547–1559.
   PubMed Web of Science ®Google Scholar
• The Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular disease (TRANSEND) Investigators. Effects of the angiotensin-receptor blocker Telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008;372(9644):1174–1183.
   PubMedGoogle Scholar
• Reboldi G, Angeli F, Cavallini C, et al. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis. J Hypertens. 2008;26(7):1282–1289.
   PubMed Web of Science ®Google Scholar
• Elgendy IS, Huo T, Chik V, et al. Efficacy and safety of angiotensin receptor blockers in older patients: a meta-analysis of randomized trials. Am J Hypertens. 2015;28(5):576–585.
   PubMed Web of Science ®Google Scholar
• Potier L, Roussel R, Elbez Y, et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high vascular . The reach registry investigatorsrisk. Heart. 2017;103(17):1339–1346.
   PubMedGoogle Scholar
• Schrader J, Luders S, Kulschewski A, et al. Evaluation of acute candesartan cilexetil therapy in stroke survivors: the ACCESS study. Stroke. 2003;34(7):1699–1703.
   PubMed Web of Science ®Google Scholar
• Schrader J, Luders S, Kulschewski A, et al. Morbidity and mortality after stroke, eprosartan compared to nitrendipine for secondary prevention. Principal results of a Prospective Randomized Controlled study (MOSES). Stroke. 2005;36(6):1218–1226.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Diener HC, Sacco RL, et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med. 2008;359(12):1225–1237.
   PubMed Web of Science ®Google Scholar
• Benjamin EJ, Blaha MJ, Chiuve SE, et al. American Heart Association Statistics Committee and stroke statistics Subcommittee. Heart disease and stroke statistics −2017 update: a report from the American Heart Association. Circulation. 2017;135(e146–):e603.
   Google Scholar
• Ovbiagele B, Nguyen-Huynh MN. Stroke epidemiology: advancing our understanding of disease mechanism and therapy. Neurotherapeutics. 2011;8(3):319–329.
   PubMed Web of Science ®Google Scholar
• Tian XU, Tao ZJ, Mei Y, et al. Dyslipidemia and outcome in patients with acute ischemic stroke. Biomed Environ Sci. 2014;27(2):106–110.
   PubMedGoogle Scholar
• Chen KN, He L, Zhong LM, et al. Meta-analysis of dyslipidemia management for prevention of ischemic stroke recurrence in China. Front Neurol. 2020;11:483570.
   PubMedGoogle Scholar
• Liao CC, Shih CC, Yeh CC, et al. Impact of diabetes on stroke risk and outcomes. Medicine (Baltimore). 2015;94:52.
   Google Scholar
• Khoury JC, Kleindorfer D, Alwell K, et al. Diabetes mellitus. A risk factor for ischemic stroke in a large biracial population. Stroke. 2013;44:1500–1504.
   PubMed Web of Science ®Google Scholar
• Tuttolomondo A, Casuccio A, Guercio G, et al. Arterial stiffness, endothelial and cognitive function in subjects with 2 diabetes in accordance with absence or presence of diabetic foot syndrome. Cardiovasc Diabetol. 2017;16:2.
   PubMedGoogle Scholar
• Liu L, Zhan L, Wang Y, et al. Metabolic syndrome and the short-term prognosis of acute ischemic stroke: a hospital-based retrospective study. Lipids Health Dis. 2015;14:76.
   PubMedGoogle Scholar
• Liang Y, Yan Z, Hao Y, et al. Metabolic syndrome in patients with first-ever ischemic stroke: prevalence and association with coronary heart disease. Scienttfic Rep. 2022;12:13042.
   PubMedGoogle Scholar
• Yen YF, Jen I, Chen M, et al. Association of cytomegalovirus end-organ disease with stroke in people living with HIV/AIDS: a nationwide population-based cohort study. PLoS One. 2016;11:e0151684.
   PubMedGoogle Scholar
• Tuttolomondo A, Di Ramondo D, Pecoraro R, et al. Early high-dose atorvastatin treatment improved serum immune-inflammatory markers and functional outcome in acute ischemic strokes classified as large artery atherosclerotic stroke. A randomized trial. Medicine (Baltimore). 2016;95:13.
   Google Scholar
• Gasiorek P, Banach M, Sakowitz A, et al. The potential role of inflammation in cryptogenic stroke. Adv Med Sci. 2019;64:381–387.
   PubMedGoogle Scholar
• Tuttolomondo A, Casuccio A, Della Corte V, et al. Endothelial function and arterial stiffness in subjects with acute ischemic stroke: relationship with TOAST subtype. Atherosclerosis. 2017;256:94–99.
   PubMed Web of Science ®Google Scholar
• Zanoli L, Boutouyrie P, Fatuzzo P, et al. Inflammation and aortic stiffness: an individual participant data meta-analysis in patients with inflammatory bowel disease. J Am Heart Assoc. 2017;6:e007003.
   PubMedGoogle Scholar
• Kodani E, Akao M. Atrial fibrillation and stroke prevention: state of the art-epidemiology and pathophysiology: new risk factors, concepts and controversies. Eur Heart Supplements. 2020;22(Suppl 0):01–013.
   Google Scholar
• Alshehri A. Stroke in atrial fibrillation: review of risk stratification and preventive therapy. J Fam Comm Med. 2019;26:92–97.
   PubMed Web of Science ®Google Scholar
• Katsanos AH, Filippatou A, Manios E, et al. Blood pressure reduction and secondary stroke prevention. A systematic review and metaregression analysis of randomized clinical trials. Hypertension. 2017;69:171–179.
   PubMed Web of Science ®Google Scholar
• Sandsdt EC, Anderson CS, Bath PM, et al. Stroke Organization (ESO) guidelines on blood pressure management in acute ischaemic stroke and intracerebral haemorrhage. Eur Stroke J. 2921;6:X48–L89.
   Google Scholar
• Mancia G. Prevention of risk factors: beta-blockade and hypertension. Eur Heart J. 2009;11(Suppl A):A3–A8.
   Google Scholar
• Friser D, Buchholz K, Haller H. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation. 2004;110:1103–1107.
   PubMedGoogle Scholar
• Hermann M, Ruschitzka F. Novel anti-inflammatory drugs in hypertension. Neprol Dial Transplnt. 2006;21:859–864.
   PubMedGoogle Scholar
• Nemati F, Rahbar-Roshndel N, Hosseini F, et al. Anti-inflammatory effects of anti-hypertensive agents: influence on interleukin-1β secretion by peripheral polymorphonuclear leukocytes from patients with essential hypertension. Clin Exper Hypertens. 2016;33:2.
   Google Scholar
• Gomes Silva IV, Carvahlo de Figueiredo R, Alves Rios DR. Effect of different classes of antihypertensive drugs on endothelial function and inflammation. Int J Mol Sci. 2019;20:3458.
   PubMed Web of Science ®Google Scholar
• Chrysant SG, Chrysant GS. Antihypertensive and cardioprotective effects of three generations of beta-adrenergic blockers: an historical perspective. Hosp Pract. 2022;50:20–196.
   Google Scholar
• Brown MJ, Brown J. Does angiotensin II protect against strokes? Lancet. 1986;2:427–429.
   PubMed Web of Science ®Google Scholar
• Andone S, Bajko Z, Motataianu A, et al. Neurorotection in strike-focus on the renin-angiotensin system: a systematic review. Int J Mol Sci. 2022;23:3876.
   PubMedGoogle Scholar
• Delavan H, Jonsson AC, Lovkvist H, et al. Cognitive function in stroke survivors: a 10-year follow-up study. Acta Neurol Scand. 2017;136:187–194.
   PubMedGoogle Scholar
• Rouch L, Cestac P, Hanon O, et al. Antihypertensive drugs prevention of cognitive decline and dementia: a systematic review of observational studies, randomized controlled trials and meta-analyses with discussion of potential mechanisms. CNS Drugs. 2015;29:113–130.
   PubMed Web of Science ®Google Scholar
• Levine DA, Galecki AT, Langa KM, et al. Trajectory of cognitive decline after incident stroke. JAMA. 2015;314:41–51.
   PubMed Web of Science ®Google Scholar
• Wiesmann M, Kiliaan AJ, Claassen JA. Vascular aspects of cognitive impairment and dementia. J Cereb Blood Flow Metab. 2013;33:1696–1706.
   PubMed Web of Science ®Google Scholar
• Saavedra JM. Evidence to consider angiotensin II receptor blockers for the early Altsheimer’s disease. Cell Mol Neuobiol. 2016;36:259–279.
   PubMedGoogle Scholar
• Alhusban A, Fouda AY, Pillai B, et al. Compound 21 is pro-angiogenic in the brain and results in sustained recovery after ischemic stroke. J Hypertens. 2015;33:170–180.
   PubMedGoogle Scholar
• Ahmed HA, Ishrat T, Pillai B, et al. Role of angiotensin system modulation on progression of cognitive impairment and brain MRI changes in aged hypertensive animals –a randomized double-blind preclinical study. Behav Brain Res. 2018;346:29–40.
   PubMedGoogle Scholar
• Chrysant SG. The role of angiotensin II receptors in stroke protection. Curr Hypertens Rep. 2012;14:202–298.
   PubMedGoogle Scholar
• Urmilla A, Rashmi P, Nilam G, et al. Recent advances in the endogenous brain renin-angiotensin system and drugs acting on it. J Renin-Angiotensin-Aldosterone Syst. 2021;2021. DOI:10.1155/202/2021/9293553.
   Google Scholar
• Faure S, Bureau A, Oudart N, et al. Protective effect of candesartan in experimental ischemic stroke in the rat mediated by AT2 and AT4 receptors. J Hypertens. 2008;26:2008–2015.
   PubMed Web of Science ®Google Scholar
• Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575–1585.
   PubMed Web of Science ®Google Scholar
• Shihab S, Boucher RE, Abraham N, et al. Influence of baseline diastolic blood pressure on the effects of intensive systolic blood pressure lowering on the risk of stroke. Hypertension. 2022;79:703–785.
   Google Scholar
• Van Rijssel AE, Stins BC, Beishon LC, et al. Effect of antihypertensive treatment on cerebral blood flow in older adults: a systematic review and meta-analysis. Hypertension. 2022;79. DOI:10.1161/HYPERTENSIONAHA.121.18255.
   PubMedGoogle Scholar
• Gallo G, Volpe M, Rubattu S. Angiotensin receptor blockers in the management of hypertension: a real-world perspective and current recommendations. Vasc Health Risk Manag. 2022;18:507–515.
   PubMed Web of Science ®Google Scholar
• Chen R, Suchard MA, Krumholz HM, et al. Comparative first-line effectiveness and safety of ACE (angiotensin converting enzyme) inhibitors and angiotensin receptor blockers. Hypertension. 2021;78:591–603.
   PubMed Web of Science ®Google Scholar